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1.  Abstract  
 
Background 
Retinoblastoma accounts for 2-4% of childhood cancers and is the most common malignant 
ocular tumour in childhood. Current treatment modalities allow, in developed countries, a 95% 
survival rate at 5 years. This is achieved by a combination of local treatments, systemic 
chemotherapy with focal treatments (CT), external beam radiotherapy (EBR) and/or 
enucleation. While enucleation causes mainly aesthetic sequelae, EBR increases the risk of 
secondary radiation induced tumours. This explains why efforts have been made to develop 
new, more conservative treatment techniques. Since a few years, intraarterial administration 
of chemotherapy (IAC), and intra-vitreous administration of chemotherapy (IVC), are used as 
new conservative treatments with the aim of avoiding enucleation and/or EBR.  
Limited data is available regarding the impact of these treatments on the health status of 
survivors and especially on their health-related quality of life (HRQoL).  
Objective   
To assess HRQoL in children and adolescents who survived retinoblastoma and compare the 
results between four different treatment modalities: enucleation, EBR, CT and IAC/IVC.  
Patients and methods 
This is a population-based cross-sectional study. Questionnaires were sent out to all 
retinoblastoma survivors who were entirely treated at our centre and who had a minimal follow-
up of 3 years since end of treatment. The HRQoL was assessed using the KIDSCREEN-52 
self-reported and parent proxy version and the total score and the scores of each dimension 
were compared between the four different treatment modalities.  
Results 
Our results showed that the perceived global HRQoL of retinoblastoma survivors was very 
good with a total score and each dimension scores over 4 on a scale of 1 to 5. With regards to 
the total quality of life score, retinoblastoma survivors who received primary CT (ref group) 
scored significantly higher than the other groups. Those who were enucleated scored lower (β 
(p-value) = -2,21 (0,04), followed by those who received IAC/IVC (-2,61 (0,02)) and the group 
that was treated with EBR (-2,96 (0,03). The CT group reported also better HRQoL on the 
school environment dimension. They scored significantly higher compared to those who were 
enucleated in the dimension of psychological well-being, and scored higher than the EBR 
group in the dimension of self- perception and autonomy. The groups did not differ in physical, 
moods and emotions, parent relations, social support and social acceptance domains. Factors 
associated with a lower score were: the older age of the patient at study time, older age at first 
examination at HOP and HJG, self-reported questionnaires and unilaterality. 
Conclusion and perspectives 
Our results show that the perceived HRQoL by retinoblastoma survivors was globally good 
and that the HRQoL differed according to the treatment received. Patients treated with EBR 
have, as expected, the worst HRQoL. To our surprise, systemic chemotherapy, although 
related to more general side effects, scored best in almost all domains, even when compared 
to the newer local chemotherapies (IAC/IVC).  
In order to confirm these data, patients who were not yet available will be included and  socio-
demographic factors such as parents’ education, migration background and country of 
residence, added since they could also affect the HRQoL. 
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2. Introduction 
 
Retinoblastoma is the most common malignant ocular tumour in childhood. Because of its 
rareness (3% of all pediatric cancers), treatment is concentrated in highly specialized centres 
comprising ophthalmologists and oncologists. Current treatment modalities allow, in developed 
countries, a 95% survival rate at 5 years1. This is achieved by a combination of focal treatments 
(cryoablation, laser photocoagulation, plaque brachytherapy, thermotherapy) with or without 
systemic chemotherapy (CT) in less advanced disease (International Classification for 
Intraocular retinoblastoma = IIRC Group B-C; Appendix 1). In the advanced stages (IIRC 
Group D-E disease), this approach is frequently ineffective leading finally to external beam 
radiotherapy (EBR) and/or enucleation2. While enucleation causes aesthetic and functional 
sequelae3, radiotherapy tremendously increases the risk of secondary radiation induced 
tumours, especially in patients with bilateral, that is, hereditary retinoblastoma presenting a 
germline mutation of RB14,5,6.  This explains why efforts have been made to develop new 
conservative treatment techniques such as intraarterial administration of chemotherapy (IAC) 
through the ophthalmic artery by inguinal catheterization7, and intra-vitreous administration of 
chemotherapy (IVC) by direct injection into the vitreous8 with the aim to avoid EBR, and also 
enucleation, and thus to improve ocular survival.   
 
The care of a child treated for retinoblastoma is very complex. Each case is unique and needs 
a treatment adapted to its particular situation. The purpose of the treatment is to preserve life, 
vision and to provide a good quality of life by avoiding EBR and enucleation. Although the 
number of survivors is increasing, literature on Health-related quality of life (HRQoL) in cured 
retinoblastoma patients remains scarce. Measurements of HRQoL allow the assessment of a 
patient’s perception of the impact of his disease treatment on daily life and late effects by 
means of validated questionnaires. In pediatric patients, these questionnaires are, depending 
on age, either self-reported, or parent proxy questionnaires. Among the studies that reported 
on HRQoL in retinoblastoma patients, Batra et al (India) 9-10 evaluated quality of life using the 
PedsQL™ 4.0 generic score scale in retinoblastoma survivors and compared the results to 
healthy siblings. In 2018, Zhang et al (China)11 evaluated HRQoL using the same 
questionnaire in retinoblastoma survivors after enucleation and compared this specific group 
with healthy children. In Switzerland, a study reported on survivors of childhood cancer in 
general, including retinoblastoma patients, and compared to healthy siblings using a Short 
Form-36 (SF-36) questionnaire12. Sheppard et al (UK) used the same two questionnaires to 
evaluate mothers’ perception of HRQoL of retinoblastoma survivors compared to the normal 
population13. Alessi et al conducted a study in Northern Italy using a 15-item Health Utilities 
Index that was specifically created to perform a population-based study of childhood cancer14. 
Finally, between 2006 and 2010, Van Dijk15,16,17 et al reported several times on HRQoL results 
of retinoblastoma survivors compared to the Dutch population using either KIDSCREEN self-
reported and proxy-reported questionnaire, Short-Form-36 disease specific questionnaire or 
PedsQL™ 4.0 questionnaire.   
 
However, none of the studies compared HRQoL between the different types of treatment within 
a group of retinoblastoma survivors. As the development of treatments over the last 25 years 
has moved from aggressive approach to obtain cure to conservative treatments aiming at cure, 
but  avoiding sequelae and improving thus the quality of life, it would be relevant to know if the 
HRQoL of the retinoblastoma survivors differs according to the treatment the patients have 
received. This also raises the question whether more conservative treatments increase the 
treatment burden and how this burden impacts on HRQoL. Thus, our trial focuses on the 
comparison of four different treatment types used during four different time periods: 
enucleation, EBR, CT and IAC/IVC.  
 
4 
 
 
3. Methods  
3.1 Patient recruitment and study procedures 
The present study had a cross-sectional design and was performed between May and 
September 2018. It was approved by the ethical committee of Vaud, Switzerland (authorization 
#2018-00460), and is compliant with the Declaration of Helsinki.  
 
Patients treated for retinoblastoma at the Jules Gonin Ophtalmic Hospital (HJG) and the 
pediatric Hematology Oncology Unit (HOP) between 1998 and 2015 were eligible,  if they had 
all their treatment performed in Lausanne and presented a follow-up of at least 3 years after 
completion of the treatment.  Characteristics of these patients were extracted from the medical 
charts at HJG and HOP and a specific data base was created. Disease-related information 
included date of birth, age at diagnosis, gender, laterality (unilateral/bilateral), date of the last 
control and treatment received. Type of treatment was categorized as (1) primary enucleation, 
(2) primary systemic chemotherapy with focal treatment, (3) secondary chemotherapy and/or 
EBR, (4) intraarterial and/or intra-vitreous chemotherapy.  
 
Eligibility criteria for inclusion were: (1) all patients with uni/bilateral retinoblastoma treated and 
followed at our institution between 1998 and 2015, (2) all disease stages described either  as 
Group I-V according to Reese-Ellsworth score, or Group A-E according to the Murphree IICR, 
(3) no extraocular or metastatic disease, (4) at least three years of follow-up since the end of 
the treatment and definite tumour control, (5) all treatment performed in Lausanne, (6) 
availability to answer the questionnaire.  
 
Patients and/or parents/legal guardians were invited to participate by a letter sent by mail. This 
letter included an explicative cover letter, a study information document, the Informed Consent 
Form, the KIDSCREEN-52 questionnaire and a return envelope. Two months were given to 
answer the questionnaire. Participants could either send back the documents or return them 
at their annual routine control check for retinoblastoma at HJG or at HOP. Non-responders 
were sent a reminder letter one month later.  
To those patients who had their annual routine control for retinoblastoma planned at HOP 
during the study time, the study was presented by the retinoblastoma nurse. Written informed 
consent was obtained after the explanation and the questionnaire was filled out at the end of 
the medical visit. One hour was given to the participant and his family to read the information, 
sign the consent and complete the questionnaire after the initial explanation. 
 
The cover letter and the Informed Consent Form were translated into four languages (French, 
German, Italian and English) and handed or sent out in the most appropriate language 
according to the patient’s and the parents/legal guardians’ origin. Patients of pediatric age 
received an age adapted information/consent form and age-adapted questionnaire (> age 13, 
age 11-13, < 11 parents’ information/consent), and could either sign the consent by themselves 
or be represented by their parents/legal guardians.   
 
3.2 Health Related Quality of Life (HRQoL) measures  
The KIDSCREEN-52 child/adolescent self-report instrument is a generic HRQoL 
questionnaire, developed within a European project18-19. The HRQoL questionnaire has been 
designed to assess children's (8–11 years) and adolescents’ (12–18 years) own perceptions 
of their subjective health and well-being.  
 
The KIDSCREEN-52 proxy research instrument is derived from the above-mentioned self-
report version and is designed to assess parental perceptions of their child's health and well-
being. It is used for children under the age of 8 years.  
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We used the KIDSCREEN-52 self-report version for retinoblastoma survivors over 8 years old 
and the KIDSCREEN-52 proxy-version for retinoblastoma survivors under 8 years old. All 
families answered only one version.    
 
Both versions of the KIDSCREEN-52 measure 10 HRQoL dimensions: Physical- (5 items), 
Psychological Well-being (6 items), Moods and Emotions (7 items), Self-Perception (5 items), 
Autonomy (5 items), Parent Relations and Home Life (6 items), Financial Resources (3 items), 
Social Support and Peers (6 items), School Environment (6 items) and Social Acceptance 
(Bullying) (3 items). The recall period for most items was one week. Each item could be scored 
between 1 (worst) and 5 (best). The score of each dimension was calculated as the sum of the 
answers to the questions of the dimension, divided by the number of questions. The 10 scores 
obtained therefore had a similar range between 1 and 5. One represents the worst score and 
5 the best score. The total quality of life score was calculated as the sum of these 10 scores, 
so its range varied between 10 and 50. 
 
The KIDSCREEN-52 was constructed and piloted in more than 3,000 European children and 
adolescents. In addition to common psychometric analyses, Item-Response-Theory Analysis 
and Structural Equation Modelling were performed to determine the optimal items and scale 
characteristics of the questionnaire. One focus of analyses was to identify items showing 
differential item functioning (DIF). The control of DIF enables comparable measurement of the 
identified quality of life dimensions across the 13 European countries. The KIDSCREEN-52 
was used in representative mail surveys of HRQoL in approximately 1800 children and their 
parents per country (total n = 22296) and normative data were produced. The final analysis 
involving national and cross-cultural analysis of the instruments confirmed the results of the 
pilot test. The sub-scales enable true cross-cultural measurement at an interval scale level by 
fulfilling the assumption of the Rasch-model and displaying no DIF.  
 
Both versions are available in 8 languages (French, German, Greek, Italian, Portuguese, 
Russian, Serbian, Spanish and English) and all eligible families received the questionnaire in 
their mother language or in English if it wasn’t available.  
 
3.3 Statistical analysis 
Data analysis was performed using the STATA software (StataCorp 2015. Stata Statistical 
Software: Release 14. College Station, TX: StataCorp LP). The socio-demographic data and 
the scores were summarized by the median and the interquartile range (iqr) for continuous 
variables and by the number and the percentage for category variables. The 10 scores 
measuring the quality of life were standardized: For each dimension, the score was calculated 
as the sum of the answers to the questions of the dimension, divided by the number of 
questions. The 10 scores obtained have therefore a similar range from 1 to 5. The total quality 
of life score was calculated as the sum of these 10 scores, so its range varied between 10 and 
50. The distribution of the different scores was clearly asymmetric and did not follow a normal 
distribution. For this, a robust linear regression model was used to compare the level of the 
scores between the four treatment groups but also to test the association between the different 
sociodemographic variables and the level of the scores. 
4. Results  
4.1 Characteristics of the study population  
Between 1998 and 2015, 426 patients were treated at HJG and HOP. One-hundred and ninety 
retinoblastoma survivors were eligible for the study according to the above mentioned criteria. 
One hundred and sixty-five patients could be contacted, whereas 25 were lost to FU or had an 
incorrect address (Fig. 1). Eighty-one out of 165 (49 %) returned the questionnaire; 78 
participants sent it back by mail and 3 participants filled out the questionnaire during their 
annual routine control for retinoblastoma at HOP. We included 78 participants in the current 
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analysis, after dropping 3 (3.85 %) who returned an incomplete questionnaire (Figure 1). 
Eighty-four participants (51%) didn’t return the questionnaire.  
 
Table 1 shows the socio-demographic data. Median age at the time of the survey of the study 
population was 12.00 (iqr=9.00) years and median age at diagnosis was 15.00 (iqr= 22.00) 
months (Figure 2). Most of the responders, 57 (73%), were over 8 years old and completed 
the questionnaire by themselves, whereas only 21 (27%) of the questionnaires were completed 
by the parents/legal guardians. Within the self-reporting group, 31 were adolescents ≥ 14 years 
old, 13 patients were between 11-13 years old and 13 were children between 8 and 11. The 
study group included 50 (64.1%) participants with unilateral and 28 (35.9 %) participants with 
bilateral disease. The proportion of male to female was 0.9.   
 
Table 2 shows the characteristics of each study group. The first group was composed of 16 
patients, 7 males and 9 females, who had had primary enucleation. All of them had had only 
one eye enucleated and received no further treatment. Fifteen presented a unilateral and one 
a bilateral disease. Mean age at evaluation was 16 (SD=3.6) years (range 9-22 years).   
 
The second group with 38 participants, had received primary systematic chemotherapy 
combined with focal treatment. It was composed of 19 males and 19 females. Eleven out of 
the 38 (29%) underwent a secondary enucleation. Twenty participants suffered from a 
unilateral and 18 from a bilateral disease. Mean age at evaluation was 11 (SD=4.6) years. 
Twenty-four patients were over the age of 8 years and responded to the questionnaire by 
themselves, and 14 children were younger, with parents completing the proxy-questionnaire.  
 
In the third group, 9 cured patients, composed of 5 males and 4 females, had received a 
secondary chemotherapy and/or an EBR. Three out of 9 underwent secondary chemotherapy 
after primary enucleation for histological risk factors. A further three had EBR directly, and the 
last three had EBR after primary chemotherapy. Three of them had a unilateral disease and 6 
a bilateral disease.  Mean age at evaluation was 15 (SD= 2.4) years, all were more than 12 
years old and completed the questionnaire themselves.  
 
The fourth group was composed of 15 participants, 6 males and 9 females, who received an 
intra-arterial and/or intra-vitreous chemotherapy. This group was the youngest one by age, 
corresponding to the most recent treatment period, with a mean age, at evaluation, of 7.5 
(SD=2.4) years. Eight children were ≥ 8 years old and completed the self-report questionnaire; 
7 were younger and their parents completed the proxy questionnaire. Twelve of them had a 
unilateral and 3 a bilateral disease.  
 
4.2 Health-Related Quality of life scores  
The HRQoL total score and each dimension score of all participants are given in Table 3. All 
the scores are very high (1 being the worst and 5 the best by dimension, whereas the range 
for total score is between 10 and 50). The median of the total score is 43.1, and the medians 
scores by dimension vary from 4.17 to 4.67, none being lower than 4.  Figure 3. illustrates the 
dimension scores by treatment group. Graphically Group 2, CT with focal treatment, did best 
in all dimensions, whereas treatment group 1, 3 and 4 showed more variation among the 
different dimensions. 
 
Group 2 (primary CT group) was taken as a reference for statistical analysis and all 
comparisons. The choice was based on the fact that this group contained the biggest number 
of patients and because primary systematic chemotherapy combined with focal treatment was 
the standard treatment for a long period of time (over 15 years). The comparison between the 
four groups and the factors influencing the differences are summarized in Table 4. The scores 
are given as the mean difference from the reference score (β) and not as an absolute value.  
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With regard to the total quality of life score, participants who received primary systemic 
chemotherapy (group 2) scored significantly higher than the other groups. Their total score 
was 44.22 points (SD=0.61). Group 1 scored lower (β (p-value) = -2.21 (0.04), followed by 
group 4 (-2.61 (0.02)) and then group 3 (-2.96 (0.03).  
 
Group 2 also scored significantly higher than all the other groups in the school environment 
dimension, with a score of 4.36 (SD=0.09) (β (p-value) = group 1(- 0.60 (<10-4)), group 3 (- 
0.73 (<10-4)), group 4 (- 0.38 (0.03)).  
 
Group 2 scored significantly higher than group 1 in the dimension of psychological well-being 
(β (p-value) = - 0.39 (0.02)) and financial resources (β (p-value) = - 0.4 (0.02)) and scored 
higher than group 3 in the dimension of self-perception (β (p-value = - 0.50 (0.05)) and 
autonomy (β (p-value) = -0.67 (0.01)). The score differences between the other groups weren’t 
significant for these dimensions.  
 
The groups did not differ in physical, moods and emotions, parent relations, social support and 
social acceptance domains. 
 
Figure 4 represents the HRQoL scores according to demographic factors. The scores by 
domain did not vary significantly between patients with unilateral or bilateral disease, although 
the latter showed a trend for better results; they were similar in females and males, but better 
in proxy evaluation than patients’ evaluation. As age at diagnosis and treatment varied among 
the treatment groups, the results were adjusted to age at study time and showed significantly 
the best total score for Group 2, that is CT with focal treatment (Figure 5).  
 
Factors associated with a lower score were analysed by a robust linear regression model and 
showed to be:   
- older age of the patient, at the study time, for total score and for physical well-being, 
moods and emotions, self-perception and school environment dimensions. 
- older age at first examination at HOP and/or HJG for financial resources and school 
environment dimensions.  
- self-reported questionnaire for physical well-being, moods and emotions and school 
environment dimensions. 
- unilaterality for psychological well-being dimension.  
- whereas gender had no significant influence on the scores.  
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5. Discussion 
5.1 Interpretation of results  
Our study assessed the HRQoL in a cohort of young retinoblastoma survivors, treated by four 
different treatment modalities during different time periods. For this evaluation the 
KIDSCREEN-52 questionnaire (child and adolescent self-report and parent proxy-report) was 
used with the aim to compare the total score and the scores of each dimension between these 
four different treatment types.   
 
Our results showed that the perceived global HRQoL of children and adolescents cured of 
retinoblastoma was very satisfactory. The total score of each treatment group was over 40 
(range 5 to 50) and all dimension scores were over 4 (range 1 to 5). Interestingly, our results 
showed that group 2 (systemic CT with focal treatment) scored significantly higher than the 
other groups in the total HRQoL and in the school environment dimension. Primary 
systematic chemotherapy combined with focal treatments was the standard treatment for a 
long period. New modalities of local chemotherapy such as intraarterial and intra-vitreous 
administration were developed in order to improve efficiency by higher concentration of 
chemotherapy close to the tumor, and to lessen general side effects such as alopecia, 
nausea/vomiting, myelosuppression with transfusion and febrile neutropenia. Our results didn’t 
show as expected better HRQoL. However, we have to take some factors into account that 
may explain this result.  
 
The age of the patients when they answered the questionnaire was a major factor that was  
associated to the scores. Patients who were older at the study time scored significantly lower 
in the total score and in four dimensions: physical well-being, moods and emotions, self-
perception and school environment. In order to take into account the age effect, we performed 
an age-adjusted analysis for all scores. The HRQoL total score of group 4 remained 
significantly lower compared to group 2, which was not the case for the other groups (Figure 
5). In other words, when adjusting to the age of the patient at study time, only the HRQoL total 
score of group 4 compared to group 2 remained significantly different. As the treatment 
modalities of group 4 were newer and the patients on average younger, the follow-up for this 
group was also much shorter with a mean of 5.2 years compared to group 2 that had  a mean 
follow up of 9.3 years.  Also did in group 2 mainly adolescents fill out the questionnaire while 
in the younger group 4 the parents were primarily in charge of filling out the questionnaire.  
 
According to our statistical analysis, there was no significant difference in the total score on 
whether the child or the parent completed the report. However, it had an influence on the score 
of 3 dimensions: physical well-being, moods and emotions and school environment. 
Retinoblastoma survivors who answered the self-reported version scored lower. Their 
perception in these very subjective fields was worse than the parents’. 
 
Other studies also compared child versus parents’ perception and found different results. In 
India, Batra et al9-10 evaluated quality of life using the PedsQL™ 4.0 generic score scale in 122 
retinoblastoma survivors and compared the results to healthy siblings. They also compared 
the child versus parent’s perspective of HRQoL. The parents reported worse results in the 
emotional health dimension, but other domains were similar to the patients’ evaluation. Van 
Dijk16 et al also reported on HRQoL results of retinoblastoma survivors, compared to the Dutch 
population, using the KIDSCREEN-52 self-report and proxy-report questionnaire and found a 
discordance between the evaluation done by 65 patients compared to their parents’ 
perception. Parents judged the HRQoL of their child to be relatively poorer in all domains, 
especially in “moods and emotions” domain,  which is again contradictory to our results. The 
mean age of the participants in their study was 12.7 years, very similar to the mean age of our 
participants  (11.7 years). Most of the Van Dijk study’s participants were treated by enucleation 
or radiotherapy whereas most of the participants of our study were treated by primary systemic 
CT. What is more relevant is that in our study, group 1 and 3 were fully composed of children 
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over 8 years old. They all answered by themselves, thus we collected only self-reported 
questionnaires for these two groups. In both previously mentioned studies, the questionnaire 
was given to both parents and patient of the same family and their responses were compared. 
We didn’t make this comparison. We only looked at it as a potential influencing factor in the 
robust linear regression model. 
 
The dimensions associated with a lower score in our study (physical well-being, moods and 
emotions and school environment) are very subjective and influenced by adolescence. As 
group 1 and 3 were composed by older children it can explain this result in our study.  
  
Concerning the school environment dimension score, group 2 scored significantly higher 
than all the other groups with a score of 4.36 versus 3.98 for group 4, 3.76 for group 1 and 
3.63 for group 3. These results remain significant when adjusted to the age of the patient at 
the study time and to the KIDSCREEN-52 version (self-reported or proxy). Generally, this 
score was still very high for the whole cohort (4.17) even when lower in some treatment groups. 
We compared these results with other studies, although it was not completely equivalent, as 
different assessment tools were used and comparisons between different groups done. The 
differences in scores for this dimension among Dutch pediatric patients with retinoblastoma 
compared to the norm population was not statistically significant16. Sheppard et al13 used the 
PedsQL™ 4.0 and the Short-Form-36 in London to evaluate mothers’ perception of HRQoL of 
retinoblastoma survivors compared to the normal population and concluded that there was 
excellent school attendance and school activities, whereas the global HRQoL score, and 
especially the physical and psychosocial functions, were lower.  An Israeli20 study reported 
that paediatric patients with retinoblastoma were affected by the disease and their daily 
activities were restricted, thus causing absences from schools and reductions in participation 
in all type of activities, which significantly affected the children’s scores in the school 
dimension. In our study, retinoblastoma survivors from groups 1 (primary enucleation) and 3 
(secondary enucleation and/or EBR) scored lower. They were more often aesthetically 
impacted and their time cure was longer, with more intensive treatments. This could have had 
consequences on their school life and psychosocial well-being and explain our results.  
 
In the dimension of psychological well-being, group 1 scored significantly lower than group 
2. Although all pediatric patients had an ocular prothesis implantation completed, an impact on 
self-perception could still be observed. There were also some personal letters sent to the study 
team reporting on the suffering after enucleation, especially during the period of adolescence, 
mainly for aesthetical reasons. An adolescent depicted in an impressive and moving way the 
loss of self-esteem related to the ocular prothesis and the difficulty in accepting this difference 
during adolescence. Two parents also reported on the bullying of their child at school for the 
same reason. This was in line with Zhan et al11 who evaluated HRQoL using the the PedsQL™ 
4.0 in 71 retinoblastoma survivors after enucleation in China. They compared this specific 
group with healthy children and found that social, school dimensions and total scores were 
significantly lower. These results were more relevant for children with bilateral eye disease, 
age at diagnosis ≥ 18 months and in those who considered ocular prosthesis unsatisfactory. 
After unilateral enucleation pediatric patients with retinoblastoma changed from binocular 
vision to monocular vision. It has been shown that patients with monocular vision experience 
many difficulties in daily activities and social role playing, which significantly affects their well-
being21.  
 
Group 3 scored significantly lower than group 2 in the dimension of self-perception and 
autonomy. The self-perception dimension is significantly associated with an older age and 
this can explain our results, as group 3 was generally composed of older patients than group 
2. When we adjusted this score to the patient’s age at study time, the significance of the 
difference between these two groups in “self-perception” disappeared. However, this was not 
the case for the autonomy dimension, which was not associated with any socio-demographic 
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factor that we considered. These are mainly patients that have received either additional 
chemotherapy or EBR for relapsing or resistant disease. Thus, their time to cure was longer, 
with more intensive treatments, which can easily induce over-protectiveness of parents 
towards their children.   
 
The scores of our four groups didn’t differ in the physical well-being dimension, not even for 
those who had undergone an enucleation. Ruegg et al12 reported on 1,593 survivors of 
childhood cancer compared to 695 healthy siblings using a Short Form-36 (SF-36) 
questionnaire in Switzerland. All survivors scored significantly lower than siblings, and 
retinoblastoma patients did particularly worse in the physical component summary. Similar 
results were found by Alessi et al14 who performed a population-based study of childhood 
cancer survivors in Northern Italy. Both studies explained that impairment was due to the poor 
vision of the retinoblastoma survivors. One possible explanation for the different results in our 
study could lie in better preserved vision due to the newer treatment techniques which would 
allow the cured patients to participate in more daily activities and sports resulting thus in better 
perception of their physical well-being. It is, however, more likely to hypothesize that our very 
intensive daily patching treatment as prevention to amblyopia, starting from the very beginning, 
regardless of the child’s age, allows a functional preservation of remaining retina even after 
various and burdensome treatment modalities. This needs to be analysed in future. 
 
The present study assessed the HRQoL of a population of retinoblastoma survivors using the 
KIDSCREEN-52 questionnaire, as did others15. Van Dijk et al also used the self-report and the 
parent proxy-report questionnaire, however they compared patients to normal populations. We 
compared HRQoL not to healthy children or siblings, but between 4 groups of treatment 
modalities, which has not been done until now. Other studies used different questionnaires 
such as either the PedsQL 4.0 generic scale questionnaire or the Short-Form-36 disease 
specific questionnaire or just a specific local questionnaire. The PedsQL 4.0 generic scale has 
only 5 health domains (physical, social, emotional, school and psychosocial) and is less 
precise than KIDSCREEN-52. The Short-Form-36 questionnaire is divided into 4 physical, and 
4 mental, components. All these questionnaires are general HRQoL instruments and measure 
only broad areas of HRQoL. They may not identify issues specifically associated with 
retinoblastoma, such as changes in facial appearance due to treatment, as the Van Dijk study 
also underlined. Thus, the difference between the studied and compared populations and 
between the assessment tools used may contribute to contradictory results and make precise 
comparison with other studies rather difficult.  
 
5.2 Strengths and limitations 
The small sample size of this study limits its statistical power. Although the questionnaire had 
been sent out to an important number of eligible cured patients, the response rate was only 49 
%. Most of the other studies who evaluated HRQoL of retinoblastoma survivors had a response 
rate that was around 60%. An explanation for the lower response rate of this study may be the 
fact that almost 50% of the patients came from abroad and received the cover letter mainly in 
English. This might have discouraged them from responding, in spite of the fact that the 
questionnaires were all in the patients’ language. It is also possible that some letters did not 
reach their destination.  
 
The heterogeneity of the origins of the survivors and their sociodemographic factors, as the 
participants lived in many different European and non-European countries, gave us certainly 
a more global aspect, but may also directly have affected the HRQoL of the participants, which 
can partially be related to cultural specificities. We didn’t collect data on sociodemographic 
factors such as parents’ education, migration background and country of residence which 
certainly could affect the quality of life. 
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Another limitation that we shared with other childhood cancer survivor studies was the use of 
self-reported health problems, as well as the bias of parents-proxy report versus child self-
report questionnaire. We used the KIDSCREEN-52 self-report version for retinoblastoma 
survivors over 8 years old and the KIDSCREEN-52 proxy version for retinoblastoma survivors 
under 8 years old. All families answered to only one version. In other studies, families 
responded to both versions and the perceptions of the parents could be compared with the 
one of the children. It would be interesting to have both opinions for all families and to compare 
the results. 
 
Another aspect are the adolescents who tend to be more critical about their conditions, without 
giving the possibility to know for sure whether the explanation is related to the age period or to 
received treatments. However, the robust linear regression model tells us that an older age at 
study time has a significant influence on a lower score given to physical, moods and emotion, 
self-perception and school environment dimensions.  
 
We decided to compare the HRQoL between 4 treatment groups within the same disease, 
which is independent of population-related norms or comparison with siblings. To our 
knowledge, this is the first time that quality of life in patients cured of retinoblastoma has been 
evaluated in relation to the specific treatments.   
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6. Conclusions and future perspectives  
 
Our results show that the perceived HRQoL by retinoblastoma survivors is globally good and 
that the HRQoL differes according to the treatment received. Patients treated with EBR have, 
as expected, the worst HRQoL. The aesthetically sequalae’s caused by enucleation had a big 
impact on the HRQoL, especially during the adolescent period. To our surprise, systemic 
chemotherapy, although related to more general side effects, scored best in almost all 
domains, even when compared to the newer local chemotherapies (IAC/IVC).  
 
This research gave us relevant results, that we didn’t expect, and allowed us to consider the 
HRQoL comparison between these four different treatment modalities as something important 
to understand the effect of the treatments on retinoblastoma survivors’ lives. It consolidates 
the efforts that have been made to develop new conservative treatment techniques with the 
aim of avoiding EBR and enucleation and encourages the use of local treatments that permit 
maintenance of good vision and with no aesthetical sequalae’s.  
 
We would like to expand our study by increasing participation in order to strengthen the 
obtained data. For this we plan to contact again the non-responders by sending the cover letter 
and the Informed Consent Form, in addition to the questionnaire, in the mother language of 
every patient in order to obtain a higher response rate. It would be also interesting to add more 
sociodemographic factors such as parents’ education, migration background and country of 
residence that certainly affect the quality of life. We used the KIDSCREEN-52 self-report 
version for retinoblastoma survivors over 8 years old and the KIDSCREEN-52 proxy version 
for retinoblastoma survivors under 8 years old. It would be interesting to send both versions to 
all families in order to compare the parent’s vision versus the retinoblastoma survivors’ vision.  
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9. Appendices  
 
Appendix 1: Classification for Intraocular retinoblastoma  
 
 
 
Table 2 International Classification System (IIRC) 
Group A Small tumors (£3mm) confined to the retina (no seeding), at least 3mm from the fovea and 1.5mm from optic nerve.  
Group B Tumors (>3mm) confined to the retina in any location, with clear subretinal fluid £ 5mm from the tumor margin 
Group C Localized vitreous and/or subretinal seeding (<5mm in total from tumor margin). If there is more than 1 site of subretinal/vitreous 
seeding, then the total of these sites must be <6mm. Up to 1 quadrant subretinal seeding may be present. 
Group D Diffuse vitreous and/or subretinal seeding (³5mm in total from tumor margin). Seeding more extensive than Group C. Retinal 
detachment >1 quadrant 
Group E Massive retinoblastoma with anatomic or functional destruction of the eye with one or more of the following 
- Neovascular glaucoma 
- Massive intravitreal hemorrhage 
- Aseptic orbital cellulitis 
- Tumor anterior to anterior vitreous face 
- Tumor touching the lens 
- Diffuse infiltrating tumor 
- Phthisis or pre-phthisis 
 
Linn Murphree A. Intraocular retinoblastoma: the case for a new group classification. Ophthalmol Clin North Am. 2005;18(1):41-
54, viii 
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Figure 1: Participants and response rate of retinoblastoma survivors  
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Figure 2: Distribution of patient’s age  
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Figure 3: HRQoL scores of all dimensions by treatment group 
 
 
 
 
  
20 
 
 
Figure 4: HRQoL scores according to demographic factors      
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Figure 5: HRQoL total score adjusted to patient’s age at study time  
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Table 1: Baseline characteristics of the cohort  
  
Participants (n=78) 
 
Age (years), median (iqr) 
 
12.00 (9.00) 
Age at first exam (months), median (iqr) 15.00 (22.00) 
Gender, n(%)  
             male 37 (47.5%) 
female 41 (52.5%) 
Laterality, n(%)  
unilateral 50 (64%) 
bilateral 28 (36%) 
KIDSCREEN-52 version, n(%)  
self-report 57 (73%) 
proxy 21 (27%) 
Treatment received, n(%)   
Primary enucleation 16 (20.5%) 
Primary systemic chemotherapy 38 (48.7%) 
Secondary chemotherapy and/or EBR 9 (11.5%) 
Intraarterial and/or intravitreous chemotherapy 15 (19.3%) 
24 
 
 
 
 
  
Table 2: Baseline characteristics of each group   
 Primary 
enucleation 
(n=16) 
Primary systemic 
chemotherapy 
(n=38) 
Secondary 
chemotherapy 
and/or EBR (n=9) 
Intraarterial and/or 
intravitreous 
chemotherapy (n=15) 
Age at evaluation (years), 
mean (SD) 
16 (3.6) 10.76 (4.6) 15 (2.4) 7.5 (2.4) 
Age at diagnosis (months), 
mean (SD)  
30.6 (19) 14.05 (13.3) 27.4 (36.9) 24.7 (17.57)  
Gender, n     
male 7 19 5 6 
female 9 19 4 9 
Laterality, n      
unilateral  15 20 3 12 
bilateral  1 18 6 3 
KIDSCREEN, n      
self-report 16 24 9 8 
proxy 0 14 0 7 
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Table 3: Total score and score per dimension of all participants  
 
Scores 
 Median (iqr) 
Physical 4.20 (1.00) 
Psychological well-being 4.50 (0.83) 
Moods and Emotions 4.43 (0.71) 
Self-Perception 4.40 (0.80) 
Autonomy 4.20 (0.80) 
Parent Relations and Home Life 4.50 (0.67) 
Financial Resources 4.67 (1.00) 
Social Support and Peers 4.17 (1.00) 
School Environment 4.17 (0.83) 
Social Acceptance (Bullying) 4.67 (0.67) 
Total Score 43.10 (6.03)  
  
  
  
Table 4: Comparison between the four treatment groups and factors influencing the results  
 
Coloured in red: significant results of the comparison between the four treatment groups  
Coloured in blue: significant factors influencing the results  
 
 
Variables / β(p-value) 
Physical Psychological 
well-being 
Moods and 
Emotions 
Self-
Perception 
Autonomy Parent 
Relations and 
Home Life 
Financial 
Resources 
 
Social 
Support and 
Peers 
School 
Environment 
Social 
Acceptance 
(Bullying) 
Total 
 
Age  - 0.04 (0.01) - 0.02 (0.12) - 0.03 (0.00) - 0.04 (0.00) - 0.02 (0.23) +0.02 (0.16) 0.00 (0.75) +0.01 (0.66)  - 0.04 (0.01) +0.01 (0.45) - 0.20 (0.04) 
Age (1st examination) - 0.01 (0.18) - 0.01 (0.06)  0.00 (0.72) 0.00 (0.85) 0.00 (0.47) 0.00 (0.58) - 0.01 (0.02) +0.01 (0.08) - 0.01 (0.02) 0.00 (0.96) - 0.01 (0.60) 
Sex (Male)   - 0.09 (0.55) - 0.02 (0.85) - 0.06 (0.57) +0.10 (0.52) 0.00 (0.98) +0.20(0.09) - 0.03 (0.82) +0.27 (0.14) - 0.01 (0.96) -0.07 (0.54) + 0.37 (0.68) 
Group 
  CT primary (ref) 
  Enucleation 
  CT second / EBR 
  IAC/IVC 
 
4.28 
- 0.34 (0.08) 
- 0.32 (0.20) 
- 0.22 (0.26) 
 
4.49  
- 0.39 (0.02) 
- 0.18 (0.38) 
- 0.25 (0.14) 
 
4.47  
- 0.19 (0.19) 
- 0.29 (0.12) 
- 0.01 (0.93) 
 
4.44 
- 0.25 (0.22) 
- 0.50 (0.05) 
- 0.06 (0.78) 
 
4.31  
- 0.26 (0.18) 
- 0.67 (0.01) 
- 0.26 (0.19) 
 
4.57  
+0.06 (0.69) 
- 0.27 (0.16) 
- 0.17 (0.27) 
 
4.67  
- 0.40 (0.03) 
- 0.33 (0.15) 
- 0.23 (0.24) 
 
4.19 
- 0.22 (0.34) 
- 0.05 (0.86) 
- 0.46 (0.06) 
 
4.36  
- 0.60 (0.00) 
- 0.73 (0.00) 
- 0.38 (0.03) 
 
4.61  
+0.07 (0.64) 
+0.28 (0.14) 
-0.26 (0.09) 
 
44.22  
- 2.21 (0.04) 
- 2.96 (0.03) 
- 2.61 (0.02) 
Laterality (Bilateral) - 0.07 (0.63) + 0.32 (0.01) - 0.01 (0.94) - 0.04 (0.78) +0.26 (0.09) +0.12 (0.32) + 0.11 (0.45) +0.18 (0.33) +0.27 (0.07) - 0.01 (0.96) + 1.08 (0.25) 
KIDSCREEN-52 version 
(self report) 
- 0.32 (0.05) - 0.11 (0.42) - 0.29 (0.02) - 0.28 (0.09) +0.13 (0.43) +0.03 (0.79) + 0.12 (0.43) +0.12 (0.57) - 0.43 (0.01) - 0.01 (0.95) - 1.79 (0.09) 
